Steven Benedict, MD
Neurology · Port Clinton, OHNPI 1982676789
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $38,476 of the $46,323 with a category attached, or 83.1%. Sanofi accounts for 68.0% of it on its own, with 27 other manufacturers making up the rest. Reporting peaked in 2019 at $32,413 and has fallen 99.9% since, to $25 in 2025.
Across 137 payments — averaging $338.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$31K
- SK Life Science, Inc.$13K
- E.r. Squibb & Sons, L.L.C.$258
- Novartis$247
- EMD Serono, Inc.$148
- Genentech USA, Inc.$110
- plus $934 from 22 others
Across 14 payments — averaging $5387.20 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Acadia Pharmaceuticals Inc$49K
- Novartis$11K
- Sanofi US Services Inc.$11K
- Sanofi$6K
What the payments were for
- Consulting fees$4,2059%
- Speaking & faculty fees$38,47683%
- Travel & lodging$7682%
- Food & beverage$2,8736%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 34 | $31,484 |
| SK Life Science, Inc. | 11 | $13,141 |
| E.r. Squibb & Sons, L.L.C. | 2 | $258 |
| Novartis | 23 | $247 |
| EMD Serono, Inc. | 3 | $148 |
| Genentech USA, Inc. | 12 | $110 |
| AbbVie(2 entities) | 5 | $90 |
| AstraZeneca | 5 | $77 |
| UCB, Inc. | 2 | $76 |
| Acorda Therapeutics, Inc | 4 | $72 |
| Acadia Pharmaceuticals Inc | 8 | $71 |
| Amgen(2 entities) | 4 | $70 |
| Biogen | 1 | $65 |
| Merz North America, Inc. | 2 | $51 |
| Averitas Pharma Inc. | 2 | $49 |
| Eisai Inc. | 3 | $45 |
| Bristol Myers Squibb | 2 | $42 |
| Jazz Pharmaceuticals Inc. | 2 | $39 |
| Mallinckrodt Enterprises LLC | 2 | $33 |
| Pfizer | 2 | $27 |
| Ceribell, Inc. | 1 | $20 |
| Biohaven Pharmaceuticals, Inc. | 1 | $19 |
| Lundbeck LLC | 1 | $17 |
| Teva Pharmaceuticals USA, Inc. | 1 | $16 |
| Tanabe Pharma America, Inc. | 1 | $16 |
| Vertical Pharmaceuticals, LLC | 1 | $15 |
| Collegium Pharmaceutical, Inc. | 1 | $13 |
| Lilly USA, LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LEMTRADA$26,304
- Cenobamate$6,548
- XCOPRI$6,493
- DISEASE STATE$4,330
- ZEPOSIA$258
- Mavenclad$125
How this compares
$46,323 in reported general payments places this provider in the 85th percentile of 702 neurology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Gabapentin | 219 | $2,845 |
| Levetiracetam | 78 | $2,479 |
| Oxcarbazepine | 90 | $2,087 |
| Primidone | 74 | $1,522 |
| Levetiracetam ErLevetiracetam | 32 | $1,481 |
| Divalproex Sodium | 35 | $1,313 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 60 | $1,221 |
| Eletriptan HbrEletriptan Hydrobromide | 13 | $1,163 |
| Tizanidine Hcl | 108 | $988 |
| Pyridostigmine Bromide | 21 | $966 |
| DilantinPhenytoin Sodium Extended | 13 | $922 |
| Duloxetine Hcl | 28 | $789 |
| Memantine Hcl | 33 | $764 |
| Lamotrigine | 30 | $735 |
| Ropinirole Hcl | 47 | $542 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerDilantin | $27 | $92213 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 702 neurology providers in Ohio.
Other neurology in Port Clinton
- Aram ZabetiCincinnati$1.6M
- Kenneth MankowskiColumbus$1.4M
- Aaron BosterColumbus$1.2M
- Martin TaylorNew Albany$821K
- Jacqueline NicholasColumbus$743K
- Lawrence ElmerToledo$687K
- Kenneth PugarCenterville$582K
- Brendan BauerSheffield Village$548K
- Geoffrey EubankColumbus$508K
- Lawrence GoldstickDayton$479K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.